Engert A, Pohl C, Diehl V
Medizinische Universitätsklinik I, Universität zu Köln, Germany.
Ann Oncol. 1992 Sep;3 Suppl 4:97-100. doi: 10.1093/annonc/3.suppl_4.s97.
Hodgkin/Reed-Sternberg (H-RS) cells express lymphoid activation markers like CD25 and CD30 which are present only on a small minority of normal cells. Currently, most experimental approaches in Hodgkin's lymphoma are aimed at targeting H-RS cells via monoclonal antibodies against CD25 and CD30: immunotoxins constructed by linking the antibody moiety chemically to deglycosylated ricin A-chain destroy up to 60% of small H-RS tumors in mice. The most potent immunotoxin is currently being scaled up for clinical trials. Other experimental strategies use bispecific constructs that, after binding to the cell surface of H-RS cells, convert prodrugs into their toxic counterparts, or employ monoclonal antibodies for active immunotherapy.
霍奇金/里德-斯特恩伯格（H-RS）细胞表达如CD25和CD30等淋巴激活标志物，这些标志物仅存在于极少数正常细胞上。目前，霍奇金淋巴瘤的大多数实验方法旨在通过针对CD25和CD30的单克隆抗体靶向H-RS细胞：通过将抗体部分化学连接至去糖基化蓖麻毒素A链构建的免疫毒素可破坏小鼠体内高达60%的小H-RS肿瘤。目前最有效的免疫毒素正在扩大规模进行临床试验。其他实验策略使用双特异性构建体，其在与H-RS细胞的细胞表面结合后，将前药转化为其毒性对应物，或采用单克隆抗体进行主动免疫治疗。
